Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2007-09-21 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-SATURNIN-LES-AVIGNON (84450), Vaucluse
PHARMACIE BLONDEL ET VAN DE WIELE : revenue, balance sheet and financial ratios
PHARMACIE BLONDEL ET VAN DE WIELE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-SATURNIN-LES-AVIGNON (84450),
this company of category PME
shows in 2024 a revenue of 1.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BLONDEL ET VAN DE WIELE (SIREN 500117924)
Indicator
2024
2023
2022
2021
2020
2019
2018
2016
Revenue
1 542 524 €
1 564 114 €
1 697 514 €
1 577 011 €
1 618 981 €
1 460 701 €
1 482 332 €
1 452 227 €
Net income
89 461 €
79 736 €
73 035 €
75 183 €
67 924 €
58 923 €
74 848 €
7 323 €
EBITDA
129 292 €
127 731 €
125 669 €
110 841 €
108 888 €
104 169 €
141 981 €
119 944 €
Net margin
5.8%
5.1%
4.3%
4.8%
4.2%
4.0%
5.0%
0.5%
Revenue and income statement
In 2024, PHARMACIE BLONDEL ET VAN DE WIELE achieves revenue of 1.5 M€. Revenue is growing positively over 8 years (CAGR: +0.8%). Slight decline of -1% vs 2023. After deducting consumption (1.1 M€), gross margin stands at 440 k€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 129 k€, representing 8.4% of revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 89 k€, i.e. 5.8% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 542 524 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
440 094 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
129 292 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
125 895 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
89 461 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
8.3%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 46%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 6.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
46.386%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
62.591%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
6.016%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
5.841
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE BLONDEL ET VAN DE WIELE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Debt ratio
195.241
142.429
121.397
110.922
91.906
72.054
56.357
46.386
Financial autonomy
29.864
37.146
40.975
42.612
47.34
51.948
57.184
62.591
Repayment capacity
68.486
10.225
14.298
12.753
11.779
9.445
7.122
5.841
Cash flow / Revenue
1.162%
6.852%
4.584%
4.602%
4.575%
4.499%
5.443%
6.016%
Sector positioning
Debt ratio
46.392024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good-6 pts over 3 years
In 2024, the debt ratio of PHARMACIE BLONDEL ET VAN ... (46.39) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
62.59%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+10 pts over 3 years
In 2024, the financial autonomy of PHARMACIE BLONDEL ET VAN ... (62.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
5.84 years2024
2022
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average-10 pts over 3 years
In 2024, the repayment capacity of PHARMACIE BLONDEL ET VAN ... (5.84) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 101.52. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.1x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
101.521
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
6.142
Liquidity indicators evolution PHARMACIE BLONDEL ET VAN DE WIELE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
105.275
106.141
102.466
144.397
133.128
100.01
86.733
101.521
Interest coverage
25.734
9.106
12.715
10.469
7.668
6.091
6.87
6.142
Sector positioning
Liquidity ratio
101.522024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch
In 2024, the liquidity ratio of PHARMACIE BLONDEL ET VAN ... (101.52) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
6.14x2024
2022
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good-7 pts over 3 years
In 2024, the interest coverage of PHARMACIE BLONDEL ET VAN ... (6.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 8 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 40 days. Excellent situation: suppliers finance 32 days of the operating cycle (retail model). Inventory turnover is 26 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 32 days of revenue, i.e. 137 k€ to permanently finance.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
137 161 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
8 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
40 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
26 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
32 j
WCR and payment terms evolution PHARMACIE BLONDEL ET VAN DE WIELE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2018
2019
2020
2021
2022
2023
2024
Operating WCR
153 239 €
162 078 €
152 030 €
152 281 €
175 726 €
172 332 €
146 229 €
137 161 €
Inventory turnover (days)
35
40
32
32
35
32
27
26
Customer payment term (days)
1
4
6
9
7
7
9
8
Supplier payment term (days)
60
53
49
44
43
44
52
40
Positioning of PHARMACIE BLONDEL ET VAN DE WIELE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE BLONDEL ET VAN DE WIELE is estimated at
1 142 777 €
(range 813 123€ - 1 674 860€).
With an EBITDA of 129 292€, the sector multiple of 9.2x is applied.
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
813k€1142k€1674k€
1 142 777 €Range: 813 123€ - 1 674 860€
NAF 5 année 2024
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
129 292 €×9.2x
Estimation1 193 942 €
782 085€ - 1 856 334€
Revenue Multiple30%
1 542 524 €×0.64x
Estimation986 728 €
827 107€ - 1 243 318€
Net Income Multiple20%
89 461 €×14.0x
Estimation1 248 942 €
869 743€ - 1 868 488€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BLONDEL ET VAN DE WIELE with other companies in the same sector:
Frequently asked questions about PHARMACIE BLONDEL ET VAN DE WIELE
What is the revenue of PHARMACIE BLONDEL ET VAN DE WIELE ?
The revenue of PHARMACIE BLONDEL ET VAN DE WIELE in 2024 is 1.5 M€.
Is PHARMACIE BLONDEL ET VAN DE WIELE profitable?
Yes, PHARMACIE BLONDEL ET VAN DE WIELE generated a net profit of 89 k€ in 2024.
Where is the headquarters of PHARMACIE BLONDEL ET VAN DE WIELE ?
The headquarters of PHARMACIE BLONDEL ET VAN DE WIELE is located in SAINT-SATURNIN-LES-AVIGNON (84450), in the department Vaucluse.
Where to find the tax return of PHARMACIE BLONDEL ET VAN DE WIELE ?
The tax return of PHARMACIE BLONDEL ET VAN DE WIELE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BLONDEL ET VAN DE WIELE operate?
PHARMACIE BLONDEL ET VAN DE WIELE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart